We build DNA computers to cure disease

What if a therapy worked like a computer inside a cell?

Our DNA computers sense and respond to multiple molecular cues at a single cell level, identify complex molecular patterns of disease with exquisite accuracy, and make it possible to cure some of the hardest-to-treat diseases of our time.
— how we build it

we write the code

The "code" is a molecular program that guides the therapy once it’s administered to the patient. To write the code, we analyze big life science datasets to understand molecular patterns of diseased and healthy patient cells. This understanding is compressed into a molecular program that tells the therapy how to act.

we compile

We "compile" the molecular program to DNA sequence in a systematic way using proprietary technologies. The resulting DNA sequence is now able to execute the instructions of the program in patient cells to target and eradicate disease.

we test

We extensively validate individual components and fully integrated therapeutic candidates in sophisticated and clinically-translatable in vitro and in vivo model settings, and iterate if needed to fine tune the performance and hit efficacy and safety targets.

Case Study

See how we built a drug to reprogram liver cancer in mice.

— The Impact

Highly precise, potent, and safe medicines. 

Our first-of-its kind approach is firmly rooted in the engineering mindset. We hope that this new approach to therapies will lead to a number of dramatic changes to patient care and clinical practice.

Undruggable Inputs

We compute in human cells using transcription factors, microRNAs, promoters and enhancers as inputs. These are important disease drivers that are by and large “undruggable” with conventional small molecule drugs or biologics. Using these inputs unlocks the treasure trove of knowledge on disease origins and progression to build therapies.

Potent Effectors

Ample knowledge exists on molecules that can kill, drive an immune response against, or reprogram cells; however, these molecules are often very toxic on their own and cannot be administered to patients. In combination with a precision molecular program, these molecules can be used as therapeutic effectors in a safe manner.

Streamlined Therapy Design

Our systematic design process generates candidates at shorter timescales, reduced cost, and a higher probability of success.

Medicine Instead of Surgery

Our approach has the potential to lead to cancer therapies that are tailored to tumor molecular patterns and are both very safe and very potent. Such therapies may one day be used also in early-stage cancer patients who will forgo surgery in favor of a medicine.

Pattern BioSciences mission is made possible by some of the most revolutionary.....

Keller Rinaudo Cliffton

Founder and CEO of Zipline

— Team

We firmly believe that complex diseases must be tackled with therapeutics that can match their complexity. Our team is uniquely positioned to deliver on this vision.

Kobi Benenson

Founder, CEO

Bartolomeo Angelici

Founder, VP Discovery Research

Linling Shen

Founder, VP Translational Research